NASDAQ:IDRAIdera Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Idera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.04 -0.09 (-4.23 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$2.00Now: $2.04▼$2.1450-Day Range$1.71MA: $1.97▼$2.6452-Week Range$0.81Now: $2.04▼$3.58Volume175,633 shsAverage Volume265,874 shsMarket Capitalization$68.90 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingIdera Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Idera Pharmaceuticals has a potential upside of 292.2% from its current price of $2.04.Amount of Analyst CoverageIdera Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesIdera Pharmaceuticals has received 380 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIdera Pharmaceuticals has received 289 “underperform” votes. (Add your “underperform” vote.)Community SentimentIdera Pharmaceuticals has received 56.80% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote “Outperform” if you believe IDRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIdera Pharmaceuticals does not currently pay a dividend.Dividend GrowthIdera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Idera Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,289,988.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Idera Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 25.66% of the stock of Idera Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Idera Pharmaceuticals are expected to grow in the coming year, from ($1.32) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Idera Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Idera Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.99 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IDRA Previous Symbol CUSIPN/A CIK861838 Webwww.iderapharma.com Phone484-348-1600Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.45 million Price / Sales47.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.39) per share Price / Book-5.23Profitability EPS (Most Recent Fiscal Year)($1.57) Net Income$-56,510,000.00 Net MarginsN/A Return on Equity-102.25% Return on Assets-41.09%Miscellaneous Employees36 Outstanding Shares33,776,000Market Cap$68.90 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $2.04 -0.09 (-4.23 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IDRA News and Ratings via Email Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter. Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions How has Idera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Idera Pharmaceuticals' stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IDRA shares have increased by 47.8% and is now trading at $2.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Idera Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Idera Pharmaceuticals. When is Idera Pharmaceuticals' next earnings date? Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Idera Pharmaceuticals. How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals Inc (NASDAQ:IDRA) posted its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.06. View Idera Pharmaceuticals' earnings history. When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work? Idera Pharmaceuticals shares reverse split on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split. What price target have analysts set for IDRA? 3 brokers have issued 12-month target prices for Idera Pharmaceuticals' stock. Their forecasts range from $7.00 to $9.00. On average, they anticipate Idera Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 292.2% from the stock's current price. View analysts' price targets for Idera Pharmaceuticals. Has Idera Pharmaceuticals been receiving favorable news coverage? News headlines about IDRA stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Idera Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Idera Pharmaceuticals. Who are some of Idera Pharmaceuticals' key competitors? Some companies that are related to Idera Pharmaceuticals include Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), Pluristem Therapeutics (PSTI), DBV TECHNOLOGIE/S (DBVT), Dyadic International (DYAI), CASI Pharmaceuticals (CASI), Fennec Pharmaceuticals (FENC), Sutro Biopharma (STRO), LogicBio Therapeutics (LOGC), GENFIT S A/ADR (GNFT), Axcella Health (AXLA), Ayala Pharmaceuticals (AYLA), Surface Oncology (SURF), INmune Bio (INMB) and Jounce Therapeutics (JNCE). View all competitors. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Anavex Life Sciences (AVXL), Proteostasis Therapeutics (PTI), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE) and Celldex Therapeutics (CLDX). Who are Idera Pharmaceuticals' key executives? Idera Pharmaceuticals' management team includes the following people: Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)Mr. John J. Kirby, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 47)Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64) What is Idera Pharmaceuticals' stock symbol? Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA." Who are Idera Pharmaceuticals' major shareholders? Idera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.07%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano. View institutional ownership trends for Idera Pharmaceuticals. Which major investors are buying Idera Pharmaceuticals stock? IDRA stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin, and Vincent Milano. View insider buying and selling activity for Idera Pharmaceuticals. How do I buy shares of Idera Pharmaceuticals? Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Idera Pharmaceuticals' stock price today? One share of IDRA stock can currently be purchased for approximately $2.04. How big of a company is Idera Pharmaceuticals? Idera Pharmaceuticals has a market capitalization of $68.90 million and generates $1.45 million in revenue each year. The biotechnology company earns $-56,510,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe. What is Idera Pharmaceuticals' official website? The official website for Idera Pharmaceuticals is www.iderapharma.com. How can I contact Idera Pharmaceuticals? Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
